文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic
侵权投诉

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study

genesis induced by VEGF.

Fig. 7. GW856553X inhibits angio-

Angiogenesis (1ng/ml) was assessed after 11 days. in response to VEGF (using alkaline phosphatase-mediated a) CD31 expression was measured conversion colorimetric of ± assay. p-NPP Data followed are by experiments, SD, representative 1-way and were of 3 similar means the ANOVA versus analysed response by in **

shows p<0.01, absence ***of p<0.001. inhibitor: Dashed *p<0.05, line cells. showing morphology of the formed (b-d)release Representative from unstimulated images tubes following stained for CD31 at day dium alone, (stimulation plus 100nM GW856553X (objective

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

c) VEGF or (with d() VEGF b) me-11, magni cation ×40).

(32). The invention of these p38 MAP kinase humans for e t but also to reduce adverse effects.

and enhance patient’s ben-human treating compounds or reducing provides symptoms methods in Lastly and not least the amounts of the tokine-driven or animals suffering from cy-inhibitors, the timing(s) of administra-such as rheumatoid arthritis, and many in ammatory diseases tion, other age the form of the compound, the dependent in ammatory or putative p38 treatment and the therapies are also considered, in order diseases (5). Combination to assess their bene t in the clinic. Po-should medical be important condition factors under to adapt treatment modalities to the tential non-steroid anti-in ammatory drugs is

limitations for the use of these 184

to prevent or treat the aforementioned clinical activity conditions lead to unwanted side effects, and their of Cox enzymes, are their which inhibition can limitation Third generation of p38 MAPK inhibi-in CNS penetration (33). tors that are currently in clinical trials will eventually permit a better charac-terisation of the role of p38 MAPK in humans selectivity pro les.

by virtue of improved kinase The lapsing inhibition of geted GSK678361, compounds, arthritis by murine p38 MAPK chronic tar-re-present study indicates that p38 MAPK as demonstrated GW856553X in and the inhibition RA may have therapeutic potential for as a therapeutic target for future use in RA if safe clinical dosing achieves adequate compound exposure. Acknowledgements

We are grateful to the staff of the Bio-logical tute of Rheumatology, Imperial College Services Unit (Kennedy Insti- London, UK) for their help in the care and maintenance of laboratory mice used in our studies; and to the Histopathology Department, London, for the sectioning and staining Charing Cross Hospital, of paw specimens. The Kennedy Insti-tute of Rheumatology is supported by the Arthritis Britain (arc). The authors also thank Ri-Research Campaign of Great chard Williams, Mino Medghalchi, Ian Buysschaert and Nasser Malik for their assistance in the in vivo studies.

1. References

FAROOQ A, lation of MAPK ZHOU phosphatases. MM: Structure Cell and Signal regu- 2. 2004, 16: 769-79.

KAMINSKA as B: MAPK therapy--from molecular targets signalling pathways

therapeutic bene ts. molecular for anti-in ammatory Biochim mechanisms Biophys Acta to 3. 2005, 1754: 253-62.

BAINBRIDGE J, MADDEN L, ESSEX D, BINKS

M, nine MALHOTRA R, PALEOLOG EM: Methio-chronic aminopeptidase-2 role for angiogenesis inhibition. collagen-induced blockade arthritis: potential reduces 4. Ther MALFAIT 2007, 9: R127.

Arthritis Res MAINI AM, WILLIAMS RO, MALIK ing homologous collagen-induced arthritis in RN, FELDMANN M: Chronic relaps-AS,

DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. 5. Arthritis Rheum ASTON NM, BAMBOROUGH P, BUCKTON JB

2001, 44: 1215-24.

et al.: p38alpha mitogen-activated protein

上一页第9页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email